Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
The purpose of this study is to determine if this epothilone leads to a response in patients with recurrent ovarian cancer that has progressed during, or in the last six months since a treatment of platinum-based chemotherapy. We also aim to look at the safety of the study drug and assess the impact of the infusion duration on tolerability.
Ovarian Neoplasms
DRUG: Sagopilone (BAY86-5302 , ZK219477)
Proportion of responders, 18 weeks
Duration of response, up to 1 year after LPLTV|Time to disease progression, up to 1 year after LPLTV|Number of participants with adverse events, Approximately 30 weeks
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.